KLF2 and cerebral cavernous malformation: Furthermore, Ponatinib, a MEKK3 inhibitor, can prevent the formation of new CCM lesions, reduce the growth of already formed lesions and normalize expression of KLF2/4 in neonatal mouse models of CCM [99].